{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:51:43Z","timestamp":1781189503711,"version":"3.54.1"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ebm-journal.org"],"crossmark-restriction":true},"short-container-title":["Exp. Biol. Med."],"abstract":"<jats:p>Ranolazine (RAN) is an acetanilide and piperazine derivative that selectively blocks the late sodium current in cardiac cells and is prescribed in adults as an add-on medication for the symptomatic management of patients with stable angina pectoris who are insufficiently managed or intolerant of first-line antianginal treatments. RAN was first approved by the U.S. Food and Drug Administration (FDA) in 2006 and the European Medicine Agency in 2008 for the treatment of chronic stable angina. RAN has no substantial effect on hemodynamic indicators, including heart rate and blood pressure. RAN also slows fatty acid oxidation, which increases glucose oxidation, lowers lactic acid generation, and optimizes heart performance. Besides its antianginal effect, RAN has recently revealed additional pharmacological properties such as neuroprotective, hepatoprotective, renal protective, cardioprotective, and antidiabetic effects and other beneficial pharmacological activities. We choose to write this current review paper to address the many hidden pharmacological and therapeutic potentials of RAN beyond its antianginal activity.<\/jats:p>","DOI":"10.3389\/ebm.2025.10604","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:10:08Z","timestamp":1756876208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Unraveling the pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight"],"prefix":"10.3389","volume":"250","author":[{"given":"Dhirendra","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Awulika","family":"Oladimeji-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abidemi James","family":"Akindele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/01.cir.93.1.135","article-title":"Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts","volume":"93","author":"McCormack","year":"1996","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s002100000378","article-title":"Evidence that ranolazine behaves as a weak beta1-and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system","volume":"363","author":"L\u00e9tienne","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3389\/fphar.2019.01367","article-title":"Antiarrhythmic properties of ranolazine: inhibition of atrial fibrillation associated TASK-1 potassium channels","volume":"10","author":"Ratte","year":"2019","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/01.res.65.4.1045","article-title":"Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H+-Na+ and Na+-Ca2+ exchange","volume":"65","author":"Tani","year":"1989","journal-title":"Circ Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"iv6","DOI":"10.1136\/hrt.2005.078790","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijcard.2015.03.324","article-title":"Antiarrhythmic properties of ranolazine: a review of the current evidence","volume":"187","author":"Gupta","year":"2015","journal-title":"Int J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00005344-199207000-00017","article-title":"Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem","volume":"20","author":"Cocco","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0091270004273992","article-title":"Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects","volume":"45","author":"Jerling","year":"2005","journal-title":"The J Clin Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clpt.2005.05.004","article-title":"Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine","volume":"78","author":"Jerling","year":"2005","journal-title":"Clin Pharmacol & Ther"},{"key":"B11","volume-title":"Medical review of safety (ranolazine)","author":"Gordon","year":"2003"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Antiischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1177\/107424840400900105","article-title":"Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials","volume":"9","author":"Chaitman","year":"2004","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1476-4598-13-264","article-title":"Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization","volume":"13","author":"Driffort","year":"2014","journal-title":"Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10585-022-10166-7","article-title":"Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine","volume":"39","author":"Qiu","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"23066","DOI":"10.1002\/jcp.28868","article-title":"Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: effects of combination with ranolazine","volume":"234","author":"Lee","year":"2019","journal-title":"J Cell Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1002\/jcp.27399","article-title":"Colorectal cancer invasiveness in vitro: predominant contribution of neonatal Nav1.5 under normoxia and hypoxia","volume":"234","author":"Guzel","year":"2019","journal-title":"J Cell Physiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bcpt.13417","article-title":"Riluzole: anti-invasive effects on rat prostate cancer cells under normoxic and hypoxic conditions","volume":"127","author":"Rizaner","year":"2020","journal-title":"Basic & Clin Pharmacol & Toxicol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.31024\/ajpp.2019.5.6.15","article-title":"Effect of ranolazine on 1, 2 - dimethyl hydrazine induced colon cancer in mice","volume":"5","author":"Pemmireddy","year":"2019","journal-title":"Asian J Pharm Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41391-019-0128-3","article-title":"Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate","volume":"22","author":"Bugan","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9660","DOI":"10.3390\/ijms21249660","article-title":"Targeting fat oxidation in mouse prostate cancer decreases tumor growth and stimulates anti-cancer immunity","volume":"21","author":"Guth","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jid.2022.08.038","article-title":"The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma","volume":"143","author":"Lasheras-Otero","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ejhf.50","article-title":"Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction","volume":"16","author":"Tocchetti","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fphys.2018.00038","article-title":"Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production","volume":"9","author":"Riccio","year":"2018","journal-title":"Front Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/OTT.S157294","article-title":"Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine","volume":"11","author":"De Lorenzo","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1111\/bph.13791","article-title":"Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction","volume":"174","author":"Cappetta","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.26355\/eurrev_202304_31927","article-title":"Ranolazine exhibits anti-inflammatory and antioxidant activities in H9c2 cardiomyocytes","volume":"27","author":"Dogan","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.stemcr.2022.02.016","article-title":"Ranolazine rescues the heart failure phenotype of PLN-deficient human pluripotent stem cell-derived cardiomyocytes","volume":"17","author":"Jiang","year":"2022","journal-title":"Stem Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"806966","DOI":"10.3389\/fmolb.2022.806966","article-title":"Ranolazine inhibits pyroptosis via regulation of miR-135b in the treatment of diabetic cardiac fibrosis","volume":"9","author":"Ren","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"118306","DOI":"10.1016\/j.lfs.2020.118306","article-title":"Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1\/NRG1 pathway","volume":"261","author":"Chen","year":"2020","journal-title":"Life Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1139\/cjpp-2018-0571","article-title":"Cardioprotective effect of ranolazine in nondiabetic and diabetic male rats subjected to isoprenaline-induced acute myocardial infarction involves modulation of AMPK and inhibition of apoptosis","volume":"97","author":"Tawfik","year":"2019","journal-title":"Can J Physiol Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"H189","DOI":"10.1152\/ajpheart.00217.2019","article-title":"Ranolazine may exert its beneficial effects by increasing myocardial adenosine levels","volume":"318","author":"Le","year":"2020","journal-title":"Am J Physiology-Heart Circulatory Physiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.rec.2015.02.027","article-title":"Cardioprotective effect of ranolazine in the process of ischemia-reperfusion in adult rat cardiomyocytes","volume":"69","author":"Calder\u00f3n-S\u00e1nchez","year":"2016","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3825042\/v1","article-title":"Ranolazine exert its beneficial effects in myocardial infarction like ischemic preconditioning mediators by increasing myocardial nitric oxide, adenosine, Bradykinin and K+ATPase Levels","author":"Tantray","year":"2024","journal-title":"Res Square"},{"key":"B36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ejphar.2016.08.001","article-title":"Ranolazine triggers pharmacological preconditioning and postconditioning in anesthetized rabbits through activation of RISK pathway","volume":"789","author":"Efentakis","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"B37","first-page":"1295","article-title":"Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure","volume":"8","author":"Feng","year":"2016","journal-title":"Am J Transl Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9625","DOI":"10.26355\/eurrev_201911_19456","article-title":"Effects of ranolazine on cardiac function in rats with heart failure","volume":"23","author":"Wang","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11587","DOI":"10.1002\/jcp.27791","article-title":"Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling","volume":"234","author":"Nie","year":"2019","journal-title":"J Cell Physiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1566524018666180608085330","article-title":"Vagal stimulation facilitates improving effects of ranolazine on cardiac function in rats with chronic ischemic heart failure","volume":"18","author":"Teng","year":"2018","journal-title":"Curr Mol Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e003565","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy","volume":"10","author":"Coppini","year":"2017","journal-title":"Circ Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2016.04.168","article-title":"Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction","volume":"217","author":"De Angelis","year":"2016","journal-title":"Int J Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"H867","DOI":"10.1152\/ajpheart.00704.2013","article-title":"Ranolazine improves diastolic function in spontaneously hypertensive rats","volume":"306","author":"Williams","year":"2014","journal-title":"Am J Physiology-Heart Circulatory Physiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jcmg.2009.09.006","article-title":"A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images","volume":"2","author":"Venkataraman","year":"2009","journal-title":"JACC: Cardiovasc Imaging"},{"key":"B45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/echo.12674","article-title":"Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease","volume":"32","author":"Tagliamonte","year":"2015","journal-title":"Echocardiography"},{"key":"B46","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","article-title":"Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease","volume":"4","author":"Mehta","year":"2011","journal-title":"JACC: Cardiovasc Imaging"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1038\/s41598-019-42239-1","article-title":"Effect of ranolazine on plasma arginine derivatives and urinary isoprostane 8-iso-PGF2\u03b1 in patients with myocardial infarction in the randomized RIMINI-trial","volume":"9","author":"Schwemer","year":"2019","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"20032","DOI":"10.1038\/s41598-020-77014-0","article-title":"Mechanisms of ranolazine pretreatment in preventing ventricular tachyarrhythmias in diabetic db\/db mice with acute regional ischemia-reperfusion injury","volume":"10","author":"Chou","year":"2020","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ph13100321","article-title":"Antiarrhythmic effect of ranolazine in combination with selective NCX-inhibition in an experimental model of atrial fibrillation","volume":"13","author":"Wolfes","year":"2020","journal-title":"Pharmaceuticals (Basel)."},{"key":"B50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000490572","article-title":"Ranolazine prevents levosimendan-induced atrial fibrillation","volume":"102","author":"Ellermann","year":"2018","journal-title":"Pharmacology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1074248419858113","article-title":"Dose-dependent effects of ranolazine on reentrant ventricular arrhythmias induced after subacute myocardial infarction in rabbits","volume":"25","author":"Moschovidis","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.hrthm.2016.08.007","article-title":"Inhibition of late sodium current attenuates ionic arrhythmia mechanism in ventricular myocytes expressing LaminA-N195K mutation","volume":"13","author":"Markandeya","year":"2016","journal-title":"Heart Rhythm"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lfs.2016.05.026","article-title":"Ranolazine improves oxidative stress and mitochondrial function in the atrium of acetylcholine-CaCl2 induced atrial fibrillation rats","volume":"156","author":"Zou","year":"2016","journal-title":"Life Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"H264","DOI":"10.1152\/ajpheart.00505.2022","article-title":"Chronic testosterone deficiency increases late inward sodium current and promotes triggered activity in ventricular myocytes from aging male mice","volume":"325","author":"Banga","year":"2023","journal-title":"Am J Physiology-Heart Circulatory Physiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.123.064561","article-title":"Ethanol-Induced atrial fibrillation results from late INa and can be prevented by ranolazine","volume":"148","author":"Mustroph","year":"2023","journal-title":"Circulation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00424-022-02754-z","article-title":"Inhibition of late sodium current via PI3K\/Akt signaling prevents cellular remodeling in tachypacing-induced HL-1 atrial myocytes","volume":"475","author":"Ko","year":"2023","journal-title":"Pfl\u00fcgers Archiv - Eur J Physiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.hrthm.2020.11.021","article-title":"Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation","volume":"18","author":"Opa\u010di\u0107","year":"2021","journal-title":"Heart Rhythm"},{"key":"B58","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2459\/JCM.0000000000000545","article-title":"Comparison of vernakalant and ranolazine in atrial fibrillation","volume":"18","author":"Frommeyer","year":"2017","journal-title":"J Cardiovasc Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/FJC.0000000000000541","article-title":"Antiarrhythmic effects of combining dofetilide and ranolazine in a model of acutely induced atrial fibrillation in horses","volume":"71","author":"Carstensen","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/jce.12597","article-title":"Funny and late: targeting currents governing heart rate in atrial fibrillation","volume":"26","author":"Daniels","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCHEARTFAILURE.114.001129","article-title":"Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure","volume":"7","author":"Burashnikov","year":"2014","journal-title":"Circ Heart Fail"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.hrthm.2015.07.025","article-title":"Selective late INa inhibition by GS-458967 exerts parallel suppression of catecholamine-induced hemodynamically significant ventricular tachycardia and T-wave alternans in an intact porcine model","volume":"12","author":"Alves Bento","year":"2015","journal-title":"Heart Rhythm"},{"key":"B63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1074248410386485","article-title":"First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia\/reperfusion model","volume":"16","author":"Kloner","year":"2011","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/ac.70.2.3073506","article-title":"Ranolazine enhances nicardipine-induced relaxation of alpha1-adrenoceptor-mediated contraction on isolated rabbit aorta","volume":"70","author":"Malavaki","year":"2015","journal-title":"Acta Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4161\/chan.22017","article-title":"Ranolazine inhibits shear sensitivity of endogenous Na+ current and spontaneous action potentials in HL-1 cells","volume":"6","author":"Strege","year":"2012","journal-title":"Channels (Austin)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/antiox11010025","article-title":"Hypochlorite-modified LDL induces arrhythmia and contractile dysfunction in cardiomyocytes","volume":"11","author":"Koyani","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3389\/fphys.2020.00922","article-title":"Ranolazine-mediated attenuation of mechanoelectric feedback in atrial myocyte monolayers","volume":"11","author":"Del-Canto","year":"2020","journal-title":"Front Physiol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"120945","DOI":"10.1016\/j.lfs.2022.120945","article-title":"Experimental hypothyroidism induces cardiac arrhythmias and ranolazine reverts and prevents the phenotype","volume":"308","author":"Souza","year":"2022","journal-title":"Life Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1124\/jpet.104.066100","article-title":"Antiarrhythmic effects of ranolazine in a Guinea pig in vitro model of long-QT syndrome","volume":"310","author":"Wu","year":"2004","journal-title":"The J Pharmacol Exp Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.hrthm.2012.01.010","article-title":"Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2","volume":"9","author":"Parikh","year":"2012","journal-title":"Heart Rhythm"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.19102\/icrm.2021.120304","article-title":"Effects of ranolazine and its combination with amiodarone on rapid pacing-induced reentrant atrial tachycardia in rabbits","volume":"12","author":"Aidonidis","year":"2021","journal-title":"J Innov Card Rhythm Management"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s00380-021-01830-1","article-title":"In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of INa, L plus IKr inhibitor ranolazine using the halothane-anesthetized dogs","volume":"36","author":"Nunoi","year":"2021","journal-title":"Heart Vessels"},{"key":"B73","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10840-020-00865-0","article-title":"Ranolazine depresses conduction of rapid atrial depolarizations in a beating rabbit heart model","volume":"62","author":"Aidonidis","year":"2021","journal-title":"J Interv Card Electrophysiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"732","DOI":"10.36660\/abc.20190220","article-title":"Inotropic and antiarrhythmic transmural actions of ranolazine in a cellular model of type 3 long QT syndrome","volume":"114","author":"Miranda","year":"2020","journal-title":"Arq Bras Cardiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/FJC.0000000000000883","article-title":"Late sodium current in atrial cardiomyocytes contributes to the induced and spontaneous atrial fibrillation in rabbit hearts","volume":"76","author":"Chu","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/europace\/euaa127","article-title":"Functional modulation of atrioventricular conduction by enhanced late sodium current and calcium-dependent mechanisms in Scn5a1798insD\/+ mice","volume":"22","author":"Rivaud","year":"2020","journal-title":"EP Europace"},{"key":"B77","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.hrthm.2018.08.033","article-title":"Arrhythmogenic cardiac alternans in heart failure is suppressed by late sodium current blockade by ranolazine","volume":"16","author":"Fukaya","year":"2019","journal-title":"Heart Rhythm"},{"key":"B78","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/jce.13849","article-title":"Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation","volume":"30","author":"Carstensen","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yjmcc.2018.08.019","article-title":"Arrhythmias precede cardiomyopathy and remodelling of Ca2+ handling proteins in a novel model of long QT syndrome","volume":"123","author":"Montnach","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1111\/jcmm.15066","article-title":"Cardiac calcium dysregulation in mice with chronic kidney disease","volume":"24","author":"Ke","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"69231","DOI":"10.18632\/oncotarget.12470","article-title":"Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.yjmcc.2016.03.012","article-title":"The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology","volume":"94","author":"Hartmann","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.hrthm.2017.07.026","article-title":"Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: an in silico approach","volume":"14","author":"Paci","year":"2017","journal-title":"Heart Rhythm"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1253\/circj.CJ-17-0128","article-title":"Ranolazine facilitates termination of ventricular tachyarrhythmia associated with acute myocardial ischemia through suppression of late INa-Mediated focal activity","volume":"81","author":"Ogawa","year":"2017","journal-title":"Circ J"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1111\/j.1540-8159.2011.03208.x","article-title":"Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks","volume":"34","author":"Bunch","year":"2011","journal-title":"Pacing Clin Electrophysiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2459\/JCM.0000000000000521","article-title":"Ranolazine therapy in drug-refractory ventricular arrhythmias","volume":"18","author":"Curnis","year":"2017","journal-title":"J Cardiovasc Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/europace\/euw200","article-title":"Ranolazine reduces atrial fibrillatory wave frequency","volume":"19","author":"Black-Maier","year":"2017","journal-title":"Europace"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","article-title":"Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-Elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"B89","doi-asserted-by":"publisher","first-page":"940","DOI":"10.4022\/jafib.940","article-title":"The effects of ranolazine on paroxysmal atrial fibrillation in patients with coronary artery disease: a preliminary observational study","volume":"6","author":"Leftheriotis","year":"2014","journal-title":"J Atr Fibrillation"},{"key":"B90","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/europace\/eut407","article-title":"Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation","volume":"16","author":"Koskinas","year":"2014","journal-title":"Europace"},{"key":"B91","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/pace.13048","article-title":"Ranolazine added to amiodarone facilitates earlier conversion of atrial fibrillation compared to amiodarone-only therapy","volume":"40","author":"Tsanaxidis","year":"2017","journal-title":"Pacing Clin Electrophysiol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"349","DOI":"10.23736\/S0026-4725.17.04349-3","article-title":"Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis","volume":"66","author":"De Vecchis","year":"2018","journal-title":"Minerva cardioangiologica"},{"key":"B93","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ijcard.2016.11.103","article-title":"Ranolazine for rhythm control in atrial fibrillation: a systematic review and meta-analysis","volume":"227","author":"Guerra","year":"2017","journal-title":"Int J Cardiol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","article-title":"The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism","volume":"8","author":"Reiffel","year":"2015","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0003319713477911","article-title":"Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery","volume":"65","author":"Simopoulos","year":"2014","journal-title":"Angiology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.amjcard.2011.04.017","article-title":"Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting","volume":"108","author":"Miles","year":"2011","journal-title":"The Am J Cardiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/fca.11.67","article-title":"Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation","volume":"7","author":"Burashnikov","year":"2011","journal-title":"Future Cardiol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2174\/157016111106140128123506","article-title":"Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery","volume":"11","author":"Tagarakis","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00392-014-0796-x","article-title":"Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries","volume":"104","author":"Hammond","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.hrthm.2016.10.008","article-title":"Role of ranolazine in the prevention and treatment of atrial fibrillation: a meta-analysis of randomized clinical trials","volume":"14","author":"Gong","year":"2017","journal-title":"Heart Rhythm"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e004370","DOI":"10.1161\/CIRCEP.116.004370","article-title":"Ranolazine for congenital Long-QT syndrome type III: experimental and long-term clinical data","volume":"9","author":"Chorin","year":"2016","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e02","DOI":"10.15420\/ecr.2022.10","article-title":"Efficacy of ranolazine to improve diastolic performance in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Putri","year":"2023","journal-title":"Eur Cardiol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"20138","DOI":"10.1038\/s41598-023-47540-8","article-title":"Anti-inflammatory reprogramming of microglia cells by metabolic modulators to counteract neurodegeneration; a new role for ranolazine","volume":"13","author":"Piano","year":"2023","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e0150619","DOI":"10.1371\/journal.pone.0150619","article-title":"Effects of ranolazine on astrocytes and neurons in primary culture","volume":"11","author":"Aldasoro","year":"2016","journal-title":"PLoS One"},{"key":"B105","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6515\/ACS.202401_40(1).20230814C","article-title":"The anti-apoptotic effect of ranolazine on cerebral protection during cardiopulmonary bypass and carotid artery surgery","volume":"40","author":"Akgul","year":"2024","journal-title":"Acta Cardiol Sin"},{"key":"B106","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/mol.113.088492","article-title":"Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels","volume":"85","author":"Kahlig","year":"2014","journal-title":"Mol Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/bph.12150","article-title":"Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons","volume":"169","author":"Peters","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"104818","DOI":"10.1016\/j.yexmp.2022.104818","article-title":"Ranolazine alleviated cardiac\/brain dysfunction in doxorubicin-treated rats","volume":"127","author":"Chunchai","year":"2022","journal-title":"Exp Mol Pathol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1267675","DOI":"10.3389\/fnins.2023.1267675","article-title":"Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia","volume":"17","author":"Samir","year":"2024","journal-title":"Front Neurosci"},{"key":"B110","doi-asserted-by":"publisher","first-page":"117557","DOI":"10.1016\/j.lfs.2020.117557","article-title":"Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: targeting Nav1.7 channels and PPAR-\u03b3","volume":"250","author":"Elkholy","year":"2020","journal-title":"Life Sci"},{"key":"B111","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/mus.27560","article-title":"Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis","volume":"66","author":"Chandrashekhar","year":"2022","journal-title":"Muscle & Nerve"},{"key":"B112","doi-asserted-by":"publisher","first-page":"12","DOI":"10.31838\/srp.2021.1.72","article-title":"Ranolazine protects the kidney from ischemia\/reperfusion injury in adult male rats by modulation of inflammatory and oxidative pathways and suppression of Notch2\/Hes1 signalling pathway","volume":"12","author":"Abbas","year":"2021","journal-title":"Syst Rev Pharm"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.31838\/ijpr\/2021.13.01.658","article-title":"The anti-apoptotic, anti-inflammatory and anti-oxidant effects of ranolazine on renal ischemia-reperfusion injury in adult Male rats","volume":"13","author":"Abbas","year":"2021","journal-title":"Int J Pharm Res"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.47750\/pnr.2022.13.S02.251","article-title":"Renoprotective potential of ranolazine in ameliorating diabetic nephropathy in a rat model of streptozotocin-induced diabetes","volume":"13","author":"Nayaka","year":"2022","journal-title":"J Pharm Negative Results"},{"key":"B115","doi-asserted-by":"publisher","first-page":"118920","DOI":"10.1016\/j.lfs.2020.118920","article-title":"Ranolazine alleviates contrast-associated acute kidney injury through modulation of calcium-independent oxidative stress and apoptosis","volume":"267","author":"Ma","year":"2021","journal-title":"Life Sci"},{"key":"B116","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MCA.0000000000001347","article-title":"Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial","volume":"35","author":"Yusuf","year":"2024","journal-title":"Coron Artery Dis"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.neuropharm.2012.01.021","article-title":"Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine","volume":"62","author":"Hirakawa","year":"2012","journal-title":"Neuropharmacology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1744-8069-6-35","article-title":"Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability","volume":"6","author":"Estacion","year":"2010","journal-title":"Mol Pain"},{"key":"B119","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/FBP.0b013e3283323c90","article-title":"Ranolazine attenuates behavioral signs of neuropathic pain","volume":"20","author":"Gould","year":"2009","journal-title":"Behav Pharmacol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1526-4637.2009.00763.x","article-title":"Ranolazine attenuation of CFA-induced mechanical hyperalgesia","volume":"11","author":"Casey","year":"2010","journal-title":"Pain Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/pme.12516","article-title":"Ranolazine attenuates mechanical allodynia associated with demyelination injury","volume":"15","author":"Gould","year":"2014","journal-title":"Pain Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"743","DOI":"10.4103\/ijmr.IJMR_1504_16","article-title":"Effect of anti-inflammatory activity of ranolazine in rat model of inflammation","volume":"148","author":"Naveena","year":"2018","journal-title":"Indian J Med Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e2207020119","DOI":"10.1073\/pnas.2207020119","article-title":"Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice","volume":"119","author":"Lenz","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B124","doi-asserted-by":"publisher","first-page":"11969","DOI":"10.3390\/ijms231911969","article-title":"Facilitation of insulin effects by ranolazine in astrocytes in primary culture","volume":"23","author":"Jord\u00e1","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.18203\/2319-2003.ijbcp20162456","article-title":"Ranolazine improves glucose and lipid homoestasis in streptozotocin induced diabetes mellitus in albino wistar rats","author":"Bashir","year":"2016","journal-title":"Int J Basic Clin Pharmacol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1124\/jpet.110.176396","article-title":"Ranolazine increases \u03b2-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice","volume":"337","author":"Ning","year":"2011","journal-title":"The J Pharmacol Exp Ther"},{"key":"B127","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.2337\/db13-1562","article-title":"Blockade of Na+ channels in pancreatic \u03b1-cells has antidiabetic effects","volume":"63","author":"Dhalla","year":"2014","journal-title":"Diabetes"},{"key":"B128","doi-asserted-by":"publisher","first-page":"13532","DOI":"10.3390\/ijms241713532","article-title":"Improvement of vascular insulin sensitivity by ranolazine","volume":"24","author":"Guerra-Ojeda","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B129","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/nu12020382","article-title":"Metabolic and cognitive effects of ranolazine in type 2 diabetes mellitus: data from an in vivo model","volume":"12","author":"Cassano","year":"2020","journal-title":"Nutrients"},{"key":"B130","doi-asserted-by":"publisher","first-page":"16160","DOI":"10.3390\/ijms232416160","article-title":"Ranolazine attenuates brain inflammation in a rat model of type 2 diabetes","volume":"23","author":"Cassano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"B132","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12629","article-title":"Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin","volume":"18","author":"Pettus","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2337\/dc09-2334","article-title":"Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome","volume":"33","author":"Chisholm","year":"2010","journal-title":"Diabetes Care"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2337\/dc14-2629","article-title":"Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes","volume":"38","author":"Eckel","year":"2015","journal-title":"Diabetes Care"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/4952447","article-title":"Ranolazine improves glycemic variability and endothelial function in patients with diabetes and chronic coronary syndromes: results from an experimental study","volume":"2021","author":"Nusca","year":"2021","journal-title":"J Diabetes Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12020-016-1181-5","article-title":"Ranolazine promotes muscle differentiation and reduces oxidative stress in C2C12 skeletal muscle cells","volume":"58","author":"Ileana","year":"2017","journal-title":"Endocrine"},{"key":"B138","doi-asserted-by":"publisher","first-page":"12251","DOI":"10.3390\/ijms222212251","article-title":"Enhanced muscle strength in dyslipidemic mice and its relation to increased capacity for fatty acid oxidation","volume":"22","author":"Tomczyk","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B139","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/metabo12070663","article-title":"Ranolazine counteracts strength impairment and oxidative stress in aged sarcopenic mice","volume":"12","author":"Torcinaro","year":"2022","journal-title":"Metabolites"},{"key":"B140","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ana.24331","article-title":"Sodium channel slow inactivation as a therapeutic target for myotonia congenita","volume":"77","author":"Novak","year":"2015","journal-title":"Ann Neurol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0000000000004229","article-title":"Open-label trial of ranolazine for the treatment of myotonia congenita","volume":"89","author":"Arnold","year":"2017","journal-title":"Neurology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.26372","article-title":"Open-label trial of ranolazine for the treatment of paramyotonia congenita","volume":"59","author":"Lorusso","year":"2019","journal-title":"Muscle & Nerve"},{"key":"B143","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5115\/acb.2016.49.1.7","article-title":"Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment","volume":"49","author":"Lee","year":"2016","journal-title":"Anat Cell Biol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/cvr\/cvu188","article-title":"Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension","volume":"104","author":"Rocchetti","year":"2014","journal-title":"Cardiovasc Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bcpt.13845","article-title":"Ranolazine exerts atrial antiarrhythmic effects in a rat model of monocrotaline-induced pulmonary hypertension","volume":"132","author":"Teixeira\u2010Fonseca","year":"2023","journal-title":"Basic & Clin Pharmacol & Toxicol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1124\/jpet.114.221861","article-title":"Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension","volume":"353","author":"Liles","year":"2015","journal-title":"The J Pharmacol Exp Ther"},{"key":"B147","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1086\/682427","article-title":"Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study","volume":"5","author":"Khan","year":"2015","journal-title":"Pulm Circ"},{"key":"B148","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cardfail.2020.10.006","article-title":"Ranolazine improves right ventricular function in patients with precapillary pulmonary hypertension: results from a double-blind, randomized, placebo-controlled trial","volume":"27","author":"Han","year":"2021","journal-title":"J Card Fail"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.healun.2016.07.015","article-title":"Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: a pilot study","volume":"35","author":"Finch","year":"2016","journal-title":"The J Heart Lung Transplant"},{"key":"B150","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1086\/683813","article-title":"Phase I safety study of ranolazine in pulmonary arterial hypertension","volume":"5","author":"Gomberg\u2010Maitland","year":"2015","journal-title":"Pulm Circ"},{"key":"B151","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/CIRCINTERVENTIONS.111.962852","article-title":"Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model","volume":"4","author":"Nieminen","year":"2011","journal-title":"Circ Cardiovasc Interventions"},{"key":"B152","first-page":"361","article-title":"A pilot study of ranolazine in patients with intermittent claudication","volume":"25","author":"Ma","year":"2006","journal-title":"Int Angiol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bcpt.13906","article-title":"The antianginal ranolazine fails to improve glycaemia in obese liver-specific pyruvate dehydrogenase deficient male mice","volume":"133","author":"Saed","year":"2023","journal-title":"Basic & Clin Pharmacol & Toxicol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"e124643","DOI":"10.1172\/jci.insight.124643","article-title":"The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity","volume":"4","author":"Batran","year":"2019","journal-title":"JCI Insight"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.22541\/au.168490817.77526721\/v1","article-title":"A potential hepatoprotective effect of ranolazine against methotrexate-induced liver injury in rats","author":"Polat","year":"2023","journal-title":"Authorea"},{"key":"B156","doi-asserted-by":"publisher","first-page":"e13616","DOI":"10.1111\/and.13616","article-title":"Protective effects of Ranolazine on testicular torsion and detorsion injury in rats","volume":"52","author":"Keseroglu","year":"2020","journal-title":"Andrologia"},{"key":"B157","doi-asserted-by":"publisher","first-page":"101087","DOI":"10.1016\/j.isci.2020.101087","article-title":"Skeletal-muscle metabolic reprogramming in ALS-SOD1G93A mice predates disease onset and is A promising therapeutic target","volume":"23","author":"Scaricamazza","year":"2020","journal-title":"iScience"},{"key":"B158","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/ejcts\/ezaa034","article-title":"Relaxant and antiadrenergic effects of ranolazine in human saphenous vein","volume":"58","author":"Marchio","year":"2020","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"B159","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ph15010031","article-title":"Ranolazine: an old drug with emerging potential; lessons from pre-clinical and clinical investigations for possible repositioning","volume":"15","author":"Rouhana","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e003196","DOI":"10.1161\/JAHA.116.003196","article-title":"Ranolazine: a contemporary review","volume":"5","author":"Rayner\u2010Hartley","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B161","doi-asserted-by":"publisher","first-page":"174787","DOI":"10.1016\/j.ejphar.2022.174787","article-title":"Role of ranolazine in heart failure: from cellular to clinic perspective","volume":"919","author":"Kaplan","year":"2022","journal-title":"Eur J Pharmacol"}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T05:10:11Z","timestamp":1756876211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":161,"alternative-id":["10.3389\/ebm.2025.10604"],"URL":"https:\/\/doi.org\/10.3389\/ebm.2025.10604","relation":{},"ISSN":["1535-3699"],"issn-type":[{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"article-number":"10604"}}